ETNB - Altimmune: A Potential Minor Player In The Massive GLP-1 Space

2024-05-28 17:45:19 ET

Summary

• Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease.
• The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results in weight loss and LDL reduction in clinical trials.
• This candidate also has potential as a treatment for metabolic dysfunction-associated steatohepatitis or MASH.
• An investment analysis around Altimmune follows in the paragraphs below.

Shares of GLP-1 concern Altimmune, Inc. ( ALT ) fell 88% peak-to-trough in 2023, only to jump around 500% in the year’s last three months – both on reactions to data from the same obesity trial. The negative response was actuated by a high dropout rate amongst patients taking pemvidutide; the positive reaction was from LDL reduction data that could separate it amongst its GLP-1 peers. However, given the huge interest in the GLP-1 space, Altimmune merited a deeper dive. A full analysis follows in the paragraphs below....

For further details see: